Barbara Weber - 02 Feb 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: Director, Executive Chair, Director
Issuer ticker: TNGX
Reported as of: 02 Feb 2026
Net transaction value: -$374,294
SEC form: 4
Accepted by SEC: 04 Feb 2026, 20:09:06 UTC
Prior SEC filing: 06 Feb 2025
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniella Beckman, as attorney-in-fact

Key filing fact

Barbara Weber filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 04 Feb 2026.

Key facts

This page summarizes Barbara Weber's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 20:09.

Change

Previous filing in this sequence was filed on 06 Feb 2025.
Current net transaction value: -$374,294.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001800670 Primary reporting owner

Weber Barbara

Relationship: Director, Executive Chair, Director
Address: C/O TANGO THERAPEUTICS, INC.,, 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature: /s/ Daniella Beckman, as attorney-in-fact
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Award

Transaction value: $0
Shares: +37,522
Change %: +2.3%
Price: $0.000000
Shares after: 1,659,773
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F1

TNGX transaction

Common Stock

Sale

Transaction value: $369,999
Shares: -30,186
Change %: -1.8%
Price: $12.26
Shares after: 1,629,587
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F2, F3

TNGX transaction

Common Stock

Sale

Transaction value: $4,295
Shares: -333
Change %: -0.02%
Price: $12.90
Shares after: 1,629,254
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNGX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +222,132
Change %
Price: $0.000000
Shares after: 222,132
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 222,132
Exercise price: $11.94
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date.

Footnote F2

The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Footnote F3

Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F4

Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F5

This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.